Research to Harness Monoclonal Antibodies for Diagnosis of Infectious Disease to Drive Diagnostic Specialty Antibodies Market at CAGR of 5.3% from 2019 to 2027: TMR Study

ALBANY, N.Y., Sept. 7, 2021 /PRNewswire/ -- The enormous market prospect of antibody-based diagnostic kits emerges from their role in specific targeting of infectious diseases. They have been used to not only for novel therapeutic targets, but also in developing more accurate diagnosis of life-threatening diseases. The growing commercial production of monoclonal antibodies is a key trend that has expanded the possibilities in the diagnostic specialty antibodies market. The global market is projected to clock the CAGR of 5.3% from 2019 to 2027.

Transparency_Market_Research_Logo

Various antibody forms have been used for assay-specific target discovery and detection. The development of polyclonal antibodies and recombinant polyclonal antibodies has caught on momentum. Some of their major diagnostic applications are in the management of hepatitis, tuberculosis, dengue, HIV, and cancer. The recurrent focus of healthcare systems on reducing the economic and social burden of infectious diseases, notably epidemics, has driven investments in commercial production of antibodies to be used as diagnostics.

Strong expertise with attention to detail makes our market research reports stand apart, Request a Report Sample here - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=54984

Key Findings of Diagnostic Specialty Antibodies Market Study

  • Prompt Response to Infectious Disease Management Spurs Clinical Applications: The growing diagnostic potential of antibodies for detecting infections for a wide range of diseases is a key aspect underpinning the production of specialty antibodies, notes the market study on diagnostic specialty antibodies. Over the past decade, they have shown potential in diagnosing lymphoid and myeloid malignancies, in developing enzyme linked immunosorbent assays and serotyping of microorganisms. The recent research has focused on exploring the diagnostic potential of these in human pancreatic cancer. The rise in public funding to control epidemics has spurred research interest in diagnostic specialty antibodies. 
  • Technological Advancements in Large-scale Production of Monoclonal Antibodies Boost Market Growth Prospects: Monoclonal antibodies (mAbs), in particular, have emerged as a remarkable tool for the diagnosis of tumors. Hence, the expanding application of these in cancer management has encouraged investments toward the development of products in the diagnostic specialty antibodies market. Over several decades, the role of diagnostic specialty antibodies in the detection of highly infectious diseases has increased. A case in point is the application of these for serological diagnosis of the Zika virus infection. A number of such studies has been funded by government agencies in developed regions. Moreover, advancements in genetic engineering and purification technologies for mAbs have enriched their diagnostic potential, notes the market study on the diagnostic specialty antibodies market.

Request for Analysis of COVID-19 Impact on Diagnostic Specialty Antibodies Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=54984

Diagnostic Specialty Antibodies Market: Drivers

  • Constantly evolving diagnostic industry in terms of product innovation that should meet cost concerns, turnaround time, and regional regulatory requirements is a key driver for investments in producing diagnostic specialty antibodies
  • Rising burden of infectious diseases the world over is a key driver of biotech industry to expand the array of assays
  • Hospitals raising awareness about detecting primary immunodeficiencies drives investments in the diagnostic specialty antibodies market

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough, ask for custom research here - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=54984

Diagnostic Specialty Antibodies Market: Regional Dynamics

  • North America held major market share in 2018. The revenue generation has been fueled by massive strides in antibody production and favorable reimbursements frameworks for disease diagnosis. The growth of the regional market is likely to be led by product development in the U.S.
  • Asia, Africa, and Latin America are expected to be potential lucrative markets. Prevalence of infectious diseases, including COVID-19 in the regions has propelled research in diagnostic assays with rapid turnaround time and increased accuracy.

Purchase Premium Research Report on Diagnostic Specialty Antibodies Market - https://www.transparencymarketresearch.com/checkout.php?rep_id=54984<ype=S

Diagnostic Specialty Antibodies Market: Competitive Dynamics

Some of the key players in the diagnostic specialty antibodies market are Aytu BioScience, Inc., Agilent Technologies, Inc., Boehringer Ingelheim International GmbH, Bio-Rad Laboratories, Inc., Abcam plc., Abbott Laboratories., Sanofi, and F. Hoffmann-La Roche Ltd.

Modernization of healthcare in terms of both infrastructure and services have pushed the healthcare industry to new heights, Stay Updated with Latest Healthcare Industry Research Reports by Transparency Market Research: 

Cancer Immunotherapy Market: The global cancer immunotherapy market is prognosticated to encounter a high rate of development over the coming years, inferable from the rise in number of people suffering from different types of cancers. In 2015, the global cancer immunotherapy market was esteemed at US$37.50 bn. its revenue is anticipated to progress at an extremely solid CAGR of 14.6% inside a conjecture period from 2016 to 2024, the global cancer immunotherapy market is required to achieve US$124.88 bn before the finish of 2024.

Monoclonal Antibody Therapeutics Market: The research report by Transparency Market Research states that the global monoclonal antibody therapeutics market was worth US$86.7 bn in 2015 and is expected to reach US$245.8 bn by 2024. Between the forecast years of 2016 and 2024, the overall market is expected to rise at a CAGR of 12.6%.

Myasthenia Gravis Market: The myasthenia gravis market is currently having a great prosperity owing to rising focus on research and development. Thus, the several drugs are in pipeline under clinical development phases which will get approved in the near future providing targeted treatment options in the management of myasthenia gravis.

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY – 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Follow Us: Twitter | LinkedIn
Blog: https://tmrblog.com
Browse PR - https://www.transparencymarketresearch.com/pressrelease/diagnostic-specialty-antibodies-market.htm

Cision View original content:https://www.prnewswire.com/news-releases/research-to-harness-monoclonal-antibodies-for-diagnosis-of-infectious-disease-to-drive-diagnostic-specialty-antibodies-market-at-cagr-of-5-3-from-2019-to-2027-tmr-study-301370163.html

SOURCE Transparency Market Research

News, commentary and research reports are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.